Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sitoiganap,Cyclophosphamide,GM-CSF
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gliovac (sitoiganap/ERC 1671) is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM,Such tumor tissue is then processed to obtain inactivated intact cells and disrupted lysed cells from different ...
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Sitoiganap,Cyclophosphamide,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 09, 2022
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients who have exhausted all other treatment options.
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
July 22, 2020
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The MAA contains observations suggesting safety and efficacy of SITOIGANAP demonstrated from the interim data of a randomized double-blind phase II trial.
Product Name : Gliovac
Product Type : Vaccine
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Sitoiganap,Cyclophosphamide,Sargramostim
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 19, 2013
Reset All
